Mirion Technologies, Inc.: directors' dealings · United States · SEC (Form 4)

About Mirion Technologies, Inc.

Mirion Technologies, Inc. (ticker: MIR) is listed on the NYSE and is headquartered in the United States, in Atlanta, Georgia. For international investors, the company sits in a highly specialized industrial niche focused on radiation safety, science and medicine. Mirion is a global provider of radiation detection, measurement, analysis, and monitoring solutions serving the nuclear, medical, defense, and research end markets. That positioning gives the business a strong technical profile, high regulatory relevance, and a defensible competitive moat built around mission-critical applications. ([ir.mirion.com](https://ir.mirion.com/?utm_source=openai)) The company’s roots trace back to a roll-up of radiation-solution businesses formed between 1950 and 2004, followed by formal corporate structuring in the mid-2000s. Over time, Mirion expanded through acquisitions and portfolio building, including healthcare-focused assets and software capabilities, before becoming a public company under the MIR symbol. That history matters for investors because it explains both the breadth of the product portfolio and the company’s long record of integrating bolt-on acquisitions into a broader platform. ([mirion.com](https://www.mirion.com/jp/about?utm_source=openai)) Mirion reports its business in two segments: Medical and Nuclear & Safety. The Medical segment includes radiation therapy quality assurance, dosimetry services, nuclear medicine applications, imaging-related workflows, and software used across the radiopharmaceutical lifecycle. Nuclear & Safety covers radiation monitoring systems, measurement and analysis instruments, laboratory and research solutions, and defense-related products such as personal radiation detection equipment. In the nuclear market, Mirion serves customers across the full plant lifecycle, including construction, operation, decommissioning, and dismantling, which helps support recurring demand and long customer relationships. ([ir.mirion.com](https://ir.mirion.com/filings/all-sec-filings/content/0001628280-25-008233/mir-20241231.htm?utm_source=openai)) From a competitive standpoint, Mirion benefits from a portfolio of highly specialized products that are difficult to substitute, especially where safety, compliance, calibration, and reliability are essential. Its solutions are embedded in regulated environments, which tends to favor established vendors with deep engineering capabilities, certification know-how, and installation history. The company also highlights a substantial R&D and engineering organization, reinforcing its technology-led model. Internationally, Mirion operates in 13 countries, giving it geographic diversification across the United States, Europe, and other markets tied to nuclear energy, healthcare, and defense. ([ir.mirion.com](https://ir.mirion.com/news-events/press-releases/detail/83/mirion-technologies-announces-mirion-medical-brand?utm_source=openai)) Recent developments remain centered on product innovation and portfolio expansion. Mirion reported full-year 2025 results on February 10, 2026, continued to launch new solutions in medical and nuclear applications, and highlighted that its Crew Active Dosimeters will be worn by astronauts on NASA’s Artemis II mission. The company also completed the acquisition of Paragon Energy in December 2025, a move that strengthens its nuclear-energy exposure and fits its long-running strategy of targeted acquisitions. Together, these events suggest a company still building scale in attractive end markets while maintaining a disciplined focus on radiation-safety technologies. ([ir.mirion.com](https://ir.mirion.com/filings/all-sec-filings/content/0001628280-26-006844/a2026-02x10exhibit991.htm?utm_source=openai))